NasdaqCM - Delayed Quote USD

Curis, Inc. (CRIS)

14.47 -0.05 (-0.34%)
At close: April 26 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
10,023.00
10,023.00
10,162.00
10,649.00
10,835.00
Cost of Revenue
212.00
212.00
257.00
533.00
534.00
Gross Profit
9,811.00
9,811.00
9,905.00
10,116.00
10,301.00
Operating Expense
58,143.00
58,143.00
62,925.00
52,181.00
35,199.00
Operating Income
-48,332.00
-48,332.00
-53,020.00
-42,065.00
-24,898.00
Net Non Operating Interest Income Expense
919.00
919.00
-3,652.00
-4,261.00
-5,032.00
Other Income Expense
--
--
--
890.00
22.00
Pretax Income
-47,413.00
-47,413.00
-56,672.00
-45,436.00
-29,908.00
Net Income Common Stockholders
-47,413.00
-47,413.00
-56,672.00
-45,436.00
-29,908.00
Diluted NI Available to Com Stockholders
-47,413.00
-47,413.00
-56,672.00
-45,436.00
-29,908.00
Basic EPS
-9.34
-8.96
-12.14
-10.00
-12.20
Diluted EPS
-9.34
-8.96
-12.14
-10.00
-12.20
Basic Average Shares
5,054.66
5,293.29
4,669.63
4,578.46
2,433.52
Diluted Average Shares
5,054.66
5,293.29
4,669.63
4,578.46
2,433.52
Total Operating Income as Reported
-48,332.00
-48,332.00
-53,020.00
-42,065.00
-24,898.00
Rent Expense Supplemental
--
--
--
617.00
695.00
Total Expenses
58,355.00
58,355.00
63,182.00
52,714.00
35,733.00
Net Income from Continuing & Discontinued Operation
-47,413.00
-47,413.00
-56,672.00
-45,436.00
-29,908.00
Normalized Income
-47,413.00
-47,413.00
-56,672.00
-45,436.00
-29,908.00
Interest Income
2,938.00
2,938.00
1,119.00
211.00
63.00
Interest Expense
2,019.00
2,019.00
4,771.00
4,472.00
5,095.00
Net Interest Income
919.00
919.00
-3,652.00
-4,261.00
-5,032.00
EBIT
-45,394.00
-45,394.00
-51,901.00
-40,964.00
-24,813.00
EBITDA
-45,139.00
-45,139.00
-51,668.00
-40,806.00
-24,669.00
Reconciled Cost of Revenue
212.00
212.00
257.00
533.00
534.00
Reconciled Depreciation
255.00
255.00
233.00
158.00
144.00
Net Income from Continuing Operation Net Minority Interest
-47,413.00
-47,413.00
-56,672.00
-45,436.00
-29,908.00
Normalized EBITDA
-45,139.00
-45,139.00
-51,668.00
-40,806.00
-24,669.00
12/31/2020 - 8/1/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RIGL Rigel Pharmaceuticals, Inc.
1.1000
0.00%
 
ADCT ADC Therapeutics SA
4.3400
-2.25%
 
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
 
BCEL Atreca, Inc.
0.0800
-6.43%
 
AFMD Affimed N.V.
5.03
+3.07%
 
MREO Mereo BioPharma Group plc
2.7400
-2.49%
 
KPTI Karyopharm Therapeutics Inc.
1.0600
0.00%
 
COCP Cocrystal Pharma, Inc.
1.5550
+2.30%
 
ALXO ALX Oncology Holdings Inc.
16.86
-0.06%
 
SWTX SpringWorks Therapeutics, Inc.
45.53
+3.01%